Ipamorelin Vs Sermorelin
Ipamorelin vs Sermorelin: GH Peptide Comparison
The short answer
Ipamorelin and sermorelin both aim to raise growth hormone (GH), but they act on different receptors: ipamorelin is a ghrelin-receptor GH secretagogue (Raun et al., 1998), while sermorelin is a GHRH analog that works on the GHRH receptor (Prakash & Goa, 1999).
This page is general educational information, research-use framing only, not medical advice. Any decision about a research compound belongs with a qualified clinician.
What is the core difference between ipamorelin and sermorelin?
The core difference is the receptor each one acts on: ipamorelin works through the ghrelin (GH secretagogue) receptor, and sermorelin works through the GHRH receptor.
Both peptides sit upstream of the same output, pituitary GH release, but they enter through different doors. Ipamorelin was characterized as a pentapeptide that mimics ghrelin signaling to trigger GH secretion (Raun et al., 1998). Sermorelin is a 29-amino-acid analog of growth hormone releasing hormone (GHRH) and acts on the GHRH receptor to prompt the pituitary to release GH; it is the shortest synthetic fragment that retains full GHRH activity (Prakash & Goa, 1999). Because the two pathways converge on the same gland, researchers describe them as complementary rather than interchangeable.
How do their mechanisms compare side by side?
Ipamorelin is a ghrelin-receptor agonist and sermorelin is a GHRH-receptor agonist, so they trigger GH through separate but parallel routes.
| Attribute | Ipamorelin | Sermorelin |
|---|---|---|
| Peptide class | GH secretagogue (ghrelin mimetic) | GHRH analog (GHRH 1-29) |
| Receptor target | GH secretagogue receptor (ghrelin receptor) | GHRH receptor |
| Reported GH selectivity | Minimal cortisol and prolactin rise reported (Raun et al., 1998) | GHRH-receptor pathway that keeps GH release under normal hypothalamic-pituitary feedback (Prakash & Goa, 1999; Walker, 2006) |
| Circulating duration | Short-acting in original characterization (Raun et al., 1998) | Short plasma half-life, on the order of minutes (Prakash & Goa, 1999; Walker, 2006) |
| Human data depth | Limited published human data | Studied in children and adults as a diagnostic and therapeutic GHRH analog (Prakash & Goa, 1999; Walker, 2006), and reviewed among GH secretagogues (Sigalos & Pastuszak, 2018) |
Note: precise half-life figures vary by study and formulation. Both are described as short-acting rather than long-lasting in the sources above. For contrast, a modified GHRH analog such as CJC-1295 was engineered to sustain GH and IGF-1 over a longer window (Teichman et al., 2006).
Why is ipamorelin often called the more "selective" peptide?
Ipamorelin is called selective because its original characterization reported GH release with little effect on cortisol and prolactin.
In the study that first described ipamorelin, the peptide raised GH while showing minimal impact on other pituitary hormones such as cortisol and prolactin (Raun et al., 1998). That selectivity is the main reason the compound draws research interest among the ghrelin-class secretagogues. Sermorelin reaches selectivity a different way: because it acts on the GHRH receptor, GH release stays subject to normal hypothalamic and pituitary feedback, which is part of why it was used as a diagnostic test for GH deficiency (Prakash & Goa, 1999). It is worth noting that not every GH secretagogue behaves cleanly on metabolic markers: the oral secretagogue MK-677, a different molecule in a related class, raised fasting glucose and lowered insulin sensitivity in one trial (Nass et al., 2008). That contrast is why receptor class and selectivity are tracked separately.
Why are ipamorelin and sermorelin sometimes paired in research?
They are sometimes paired because each one activates a different receptor, so together they can stimulate GH release through two pathways rather than one.
A GHRH analog like sermorelin signals through the GHRH receptor (Prakash & Goa, 1999), while a ghrelin-class secretagogue like ipamorelin signals through the GH secretagogue receptor (Raun et al., 1998). Because these are distinct upstream inputs to the same pituitary output, combining a GHRH-pathway agent with a ghrelin-pathway agent is a common design theme in GH-axis research, and reviews of GH secretagogues discuss both classes side by side (Sigalos & Pastuszak, 2018). This page does not describe how to combine them, in what amounts, or on what schedule. Combination questions carry their own safety considerations and belong with a qualified clinician.
What does the research report about dosing?
Published characterizations describe these peptides at the mechanism and receptor level; this page frames any amounts as research-reported, not as advice.
The primary sources here are pharmacology and characterization studies rather than large weight or body-composition trials. Raun et al., 1998 described ipamorelin as a selective GH secretagogue in a preclinical and early-characterization context, and Prakash & Goa, 1999 review sermorelin as a GHRH analog used for diagnosis and treatment of growth hormone deficiency. Neither is presented here as a personal protocol. Any specific amount, frequency, or route is a clinical decision, and this page does not provide one.
Keep reading
Related research and verification
Ipamorelin Vs Sermorelin: FAQ
Sourcing research-grade peptides?
Talk to the Peptara Labs team about purity, third-party certificates of analysis, and cold-chain shipping.
References
- Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. doi:10.1530/eje.0.1390552 (PMID 9849822). Original characterization of ipamorelin as a ghrelin-receptor GH secretagogue that raised GH with minimal cortisol and prolactin effect.
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157 (PMID 18031173). Review of sermorelin as a GHRH analog and the shortest fragment retaining full GHRH activity, used for diagnosis and treatment of growth hormone deficiency.
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging. 2006;1(4):307-308 (PMC2699646). Supports sermorelin acting through the GHRH receptor to preserve normal hypothalamic and pituitary feedback on GH release.
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805. doi:10.1210/jc.2005-1536 (PMID 16352683). Cited for contrast as a modified GHRH analog engineered to sustain GH and IGF-1 over a longer window than short-acting peptides.
- Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized, controlled trial. Annals of Internal Medicine. 2008;149(9):601-611 (PMID 18981485). Cited for the contrast that the oral secretagogue MK-677 raised fasting glucose and lowered insulin sensitivity, unlike the reported selectivity of ipamorelin.
- Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sexual Medicine Reviews. 2018;6(1):45-53 (PMC5632578). Review that discusses ghrelin-class and GHRH-class GH secretagogues side by side.
General educational information only, research-use framing, not medical advice. Confirm the current status where you live and consult a qualified professional before acting.